يعرض 1 - 5 نتائج من 5 نتيجة بحث عن 'Seyed Reza Mousavi (13223324)', وقت الاستعلام: 0.01s تنقيح النتائج
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. حسب Seyed Reza Mousavi (13223324)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. حسب Seyed Reza Mousavi (13223324)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. حسب Seyed Reza Mousavi (13223324)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. حسب Seyed Reza Mousavi (13223324)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. حسب Seyed Reza Mousavi (13223324)

    منشور في 2025
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: